<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02154243</url>
  </required_header>
  <id_info>
    <org_study_id>2013-114</org_study_id>
    <nct_id>NCT02154243</nct_id>
  </id_info>
  <brief_title>An Open Label Trial to Decrease Signs and Symptoms of Orthostatic Hypotension Using Midodrine or Intravenous Fluid Bolus in Patients Following Total Hip Arthroplasty</brief_title>
  <official_title>An Open Label Trial to Decrease Signs and Symptoms of Orthostatic Hypotension Using Midodrine in Patients With Preserved Cardiac Output (CO) and an Intravenous Fluid Bolus for Patients With Low CO Following Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Orthostatic hypotension following total hip arthroplasty is known to limit the ability of
      patients to perform physical therapy (PT) and increase the length of hospital stay and costs.
      Our goal is to prospectively study the effects of oral midodrine on the signs and symptoms of
      orthostatic hypotension in 20 patients and the effects of intravenous fluid on the signs of
      symptoms of orthostatic hypotension in 10 patients. Midodrine will be administered to
      patients with suspected low SVV, and an intravenous fluid bolus will be administered to
      patients with low CO. 120 patients will be consented with a view to studying 30 patients who
      meet the inclusion criteria for orthostatic hypotension. Patients who receive midodrine or
      the fluid bolus will undergo hemodynamic measurements at 30 min, 1 hr, 2 hrs, 3 hrs, and 4
      hrs post-intervention. All patients will undergo measurements for blood pressure, arterial
      augmentation index, and heart rate at baseline (pre-op; holding area) and the time of first
      PT attempt. Patients will be monitored up to post-operative day 3. The working hypothesis is
      that midodrine or fluid therapy will significantly raise the mean arterial blood pressure
      (MAP) by 5 mmHg+ and/or cause a significant change in the Orthostatic Hypotension
      Questionnaire (characterized by a two-point improvement in symptom score).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Orthostatic Hypotension Questionnaire Score</measure>
    <time_frame>From baseline assessment to post-intervention (30 min, 1 hr, 2 hrs, 3 hrs, 4 hrs)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Length of the hospital stay (average of 4 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Orthostatic Hypotension</condition>
  <arm_group>
    <arm_group_label>Midodrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV&lt;15 will be given oral midodrine, 10 mg, once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous fluid bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV&gt;=15 will be given intravenous fluid bolus, 15 cc/kg, once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (no intervention)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients who are NOT diagnosed with orthostatic hypotension at their first physical therapy session will be given the interventions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <description>10 mg, p.o., once, on day of surgery after first physical therapy session</description>
    <arm_group_label>Midodrine</arm_group_label>
    <other_name>ProAmatine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intravenous fluid bolus</intervention_name>
    <description>15 cc/kg, once, on day of surgery after first physical therapy session</description>
    <arm_group_label>Intravenous fluid bolus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of participating surgeons undergoing unilateral primary total hip
             arthroplasty

          -  Ages 18-90

          -  English-speaking

          -  If the patients are diagnosed with orthostatic hypotension (fall in SBP of at least 20
             mmHg or DBP of at least 10 mmHg within 3 min of assuming a sitting/standing position)

        Exclusion Criteria:

          -  Body mass index &gt; 40

          -  Low ejection fraction (&lt;50%)

          -  Clinical diagnosis of congestive heart failure

          -  Aortic insufficiency characterized as greater than moderate

          -  Severe uncontrolled hypertension

          -  Symptomatic bradycardia (HR &lt; 50 bpm and symptoms)

          -  Creatinine &gt; 1.2 mg/dl

          -  Hepatic insufficiency

          -  Severe respiratory disease in which supplemental oxygen is required

          -  History of severe urinary retention

          -  Use of MAO inhibitors

          -  Severe supine hypertension (SBP &gt;= 150 mmHg or DBP &gt;= 90 mmHg)

          -  History of visual problems and using fludrocortisone acetate

          -  Contraindication for repeated BP measurements

          -  Revision THA and additional procedures

          -  Clonidine use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2014</study_first_posted>
  <results_first_submitted>March 23, 2017</results_first_submitted>
  <results_first_submitted_qc>July 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2017</results_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Midodrine</title>
          <description>Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV&lt;15 will be given oral midodrine, 10 mg, once.
Midodrine: 10 mg, p.o., once, on day of surgery after first physical therapy session</description>
        </group>
        <group group_id="P2">
          <title>Intravenous Fluid Bolus</title>
          <description>Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV&gt;=15 will be given intravenous fluid bolus, 15 cc/kg, once.
Intravenous fluid bolus: 15 cc/kg, once, on day of surgery after first physical therapy session</description>
        </group>
        <group group_id="P3">
          <title>Control (no Intervention)</title>
          <description>Patients who are NOT diagnosed with orthostatic hypotension at their first physical therapy session will be given the interventions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Midodrine</title>
          <description>Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV&lt;15 will be given oral midodrine, 10 mg, once.
Midodrine: 10 mg, p.o., once, on day of surgery after first physical therapy session</description>
        </group>
        <group group_id="B2">
          <title>Intravenous Fluid Bolus</title>
          <description>Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV&gt;=15 will be given intravenous fluid bolus, 15 cc/kg, once.
Intravenous fluid bolus: 15 cc/kg, once, on day of surgery after first physical therapy session</description>
        </group>
        <group group_id="B3">
          <title>Control (no Intervention)</title>
          <description>Patients who are NOT diagnosed with orthostatic hypotension at their first physical therapy session will be given the interventions.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="4"/>
                    <count group_id="B4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="11.3"/>
                    <measurement group_id="B2" value="55.7" spread="11.2"/>
                    <measurement group_id="B3" value="57.7" spread="11.2"/>
                    <measurement group_id="B4" value="55.9" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="4"/>
                    <count group_id="B4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="4"/>
                    <count group_id="B4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Orthostatic Hypotension Questionnaire Score</title>
        <time_frame>From baseline assessment to post-intervention (30 min, 1 hr, 2 hrs, 3 hrs, 4 hrs)</time_frame>
        <population>DATA WAS NOT COLLECTED. STUDY TERMINATED EARLY.</population>
        <group_list>
          <group group_id="O1">
            <title>Midodrine</title>
            <description>Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV&lt;15 will be given oral midodrine, 10 mg, once.
Midodrine: 10 mg, p.o., once, on day of surgery after first physical therapy session</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Fluid Bolus</title>
            <description>Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV&gt;=15 will be given intravenous fluid bolus, 15 cc/kg, once.
Intravenous fluid bolus: 15 cc/kg, once, on day of surgery after first physical therapy session</description>
          </group>
          <group group_id="O3">
            <title>Control (no Intervention)</title>
            <description>Patients who are NOT diagnosed with orthostatic hypotension at their first physical therapy session will be given the interventions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Orthostatic Hypotension Questionnaire Score</title>
          <population>DATA WAS NOT COLLECTED. STUDY TERMINATED EARLY.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay</title>
        <time_frame>Length of the hospital stay (average of 4 days)</time_frame>
        <population>DATA WAS NOT COLLECTED. STUDY TERMINATED EARLY.</population>
        <group_list>
          <group group_id="O1">
            <title>Midodrine</title>
            <description>Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV&lt;15 will be given oral midodrine, 10 mg, once.
Midodrine: 10 mg, p.o., once, on day of surgery after first physical therapy session</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Fluid Bolus</title>
            <description>Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV&gt;=15 will be given intravenous fluid bolus, 15 cc/kg, once.
Intravenous fluid bolus: 15 cc/kg, once, on day of surgery after first physical therapy session</description>
          </group>
          <group group_id="O3">
            <title>Control (no Intervention)</title>
            <description>Patients who are NOT diagnosed with orthostatic hypotension at their first physical therapy session will be given the interventions.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay</title>
          <population>DATA WAS NOT COLLECTED. STUDY TERMINATED EARLY.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Midodrine</title>
          <description>Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV&lt;15 will be given oral midodrine, 10 mg, once.
Midodrine: 10 mg, p.o., once, on day of surgery after first physical therapy session</description>
        </group>
        <group group_id="E2">
          <title>Intravenous Fluid Bolus</title>
          <description>Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV&gt;=15 will be given intravenous fluid bolus, 15 cc/kg, once.
Intravenous fluid bolus: 15 cc/kg, once, on day of surgery after first physical therapy session</description>
        </group>
        <group group_id="E3">
          <title>Control (no Intervention)</title>
          <description>Patients who are NOT diagnosed with orthostatic hypotension at their first physical therapy session will be given the interventions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Haskins</name_or_title>
      <organization>HSS</organization>
      <phone>(212) 606-1000</phone>
      <email>HaskinsS@hss.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

